Marea Therapeutics CSO and co-founder Ethan Weiss (L) and CEO Josh Lehrer
June 18, 2024 07:00 AM EDTUpdated 03:27 PM
Financing
Startups

Marea Ther­a­peu­tics launch­es with $190M, see­ing a 'fix­able prob­lem' in a ne­glect­ed car­diometa­bol­ic tar­get

Andrew Dunn

Senior Biopharma Correspondent

A Third Rock Ven­tures-in­cu­bat­ed start­up called Marea Ther­a­peu­tics de­buted Tues­day with $190 mil­lion to ad­vance a drug for a ge­net­ic tar­get for car­diometa­bol­ic dis­eases. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times